Identify hit compounds active against Leishmania donovani from an innovative screening collaboration with Pfizer
last phase of drug development
updated 31 Dec 2016
DNDi identified an interesting new hit compound active against Leishmania donovani from an innovative screening collaboration with Pfizer. DNDi has subsequently prepared more than 700 novel compounds in VL series 12. These structures (see link to .sdf file below) form the basis for further optimisation by DNDi’s Lead Optimization consortium, with additional expert scientific support from Takeda Pharmaceutical Company Limited, and with generous financial support from the GHIT Fund. Further details of this project will be published in due course.
- Download compound structures [SDF | 2MB]
News & resources
- 26 May 2015 - GHIT Fund invests $4 million into Takeda Pharmaceutical Company Limited and DNDi partnership to develop new visceral leishmaniasis drug
- 22 April 2014 - The role of modern drug discovery in the fight against neglected and tropical diseases, Medicinal Chemistry Communication
- 18 November 2009 - Pfizer and DNDi Advancing International Research Efforts in The Fight Against Neglected Tropical Diseases
Get our latest news, personal stories, research articles, and job opportunities.